Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.

Journal of thrombosis and thrombolysis - 1 Dec 2002

Linder Mark W, Looney Stephen, Adams Jesse E, Johnson Nancy, Antonino-Green Deborah, Lacefield Nichole, Bukaveckas Bonny L, Valdes Roland

Abstract excerpt

BACKGROUND: The dose response relationship of warfarin is unpredictable. Polymorphism of the Cytochrome P4502C9 enzyme leads to warfarin hypersensitivity presumably due to decreased metabolism of the S-enantiomer. The purpose of this study was to further characterize the relationship between CYP2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Aged, 80 and over
Share to Analysis of Variance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Chi-Square Distribution

Share to Cytochrome P-450 CYP2C9

Share to Polymorphism, Genetic

Share to Warfarin

Source

Identifiers

PMID: 12913403
DOI: 10.1023/a:1025052827305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12913403-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.PMID 12913403Read ↗

Cytochrome P450 polymorphisms are associated with reduced warfarin dose.Semantic proximity Read ↗

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.Semantic proximity Read ↗

Interindividual variability in sensitivity to warfarin--Nature or nurture?Semantic proximity Read ↗

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.Semantic proximity Read ↗

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.Semantic proximity Read ↗

Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.Semantic proximity Read ↗

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Semantic proximity Read ↗

Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.Semantic proximity Read ↗

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.Semantic proximity Read ↗

Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.Semantic proximity Read ↗

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.